Immunitybio (IBRX) Stock Price
Immunitybio Price
Over the last 12 years Immunitybio grew revenue by 54.8% annually, reaching 113.29 M USD. For Immunitybio, the net margin of -310.2% is up versus -37,129.6% a few years ago. The consensus 12-month price target for Immunitybio is 9.18 USD, about 15.5% above where the stock trades today. Of 11 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 302% above its 52-week low.
Immunitybio stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Immunitybio over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Immunitybio stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Immunitybio's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Immunitybio Price |
|---|---|
| 9/2/2026 | 7.95 USD |
| 9/1/2026 | 7.87 USD |
| 8/31/2026 | 7.95 USD |
| 8/30/2026 | 7.95 USD |
| 8/28/2026 | 8.07 USD |
| 8/27/2026 | 8.64 USD |
| 8/26/2026 | 8.25 USD |
| 8/25/2026 | 8.19 USD |
| 8/24/2026 | 7.62 USD |
| 8/21/2026 | 7.79 USD |
| 8/20/2026 | 7.84 USD |
| 8/19/2026 | 8.06 USD |
| 8/18/2026 | 7.59 USD |
| 8/14/2026 | 7.57 USD |
| 8/13/2026 | 7.65 USD |
| 8/12/2026 | 7.61 USD |
| 8/10/2026 | 7.53 USD |
| 8/7/2026 | 7.64 USD |
| 8/6/2026 | 7.32 USD |
| 8/5/2026 | 7.31 USD |
| 8/4/2026 | 6.84 USD |
| 8/3/2026 | 7.15 USD |
| 7/31/2026 | 7.17 USD |
| 7/30/2026 | 7.45 USD |
| 7/29/2026 | 6.86 USD |
| 7/27/2026 | 7.03 USD |
| 7/23/2026 | 7.40 USD |
| 7/22/2026 | 7.51 USD |
| 7/21/2026 | 8.07 USD |
| 7/20/2026 | 7.49 USD |
Immunitybio Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunitybio Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | 0.01 | 0.11 | 0.23 | 0.44 | 1.09 | 1.80 | 2.55 |
| – | – | – | – | – | – | – | – | – | – | 707.14 | 99.12 | 96.00 | 146.26 | 65.56 | 41.55 |
| – | – | – | – | – | – | – | – | – | 100.00 | 99.12 | 99.12 | 99.12 | 99.12 | 99.12 | 99.12 |
| 0.11 | 0.11 | 0.11 | – | -0.01 | 0.11 | 0.11 | 0.11 | 0.11 | 0.01 | 0.11 | 0.22 | 0.44 | 1.08 | 1.78 | 2.52 |
| -0.24 | -0.12 | -0.10 | -0.10 | -0.07 | -0.22 | -0.34 | -0.37 | -0.46 | -0.28 | -0.24 | -0.77 | -0.01 | 0.65 | 1.12 | 1.73 |
| – | – | – | – | – | – | – | – | – | -2,007.14 | -213.27 | -341.33 | -1.81 | 59.48 | 62.46 | 68.13 |
| -236.00 | -120.00 | -96.00 | -96.00 | -65.00 | -221.00 | -346.00 | -416.00 | -583.00 | -413.00 | -351.00 | -669.00 | -99.00 | 261.00 | 606.00 | 972.00 |
| 3,833.33 | -49.15 | -20.00 | – | -32.29 | 240.00 | 56.56 | 20.23 | 40.14 | -29.16 | -15.01 | 90.60 | -85.20 | -363.64 | 132.18 | 60.40 |
| 326.30 | 328.55 | 316.15 | 325.05 | 331.82 | 383.18 | 397.12 | 403.64 | 590.73 | 734.54 | 989.68 | 989.68 | 989.68 | 989.68 | 989.68 | 989.68 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Immunitybio generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Immunitybio retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Immunitybio's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Immunitybio has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Immunitybio's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Immunitybio stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunitybio Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunitybio business model & stock analysis
Immunitybio SWOT Analysis
Strengths
Immunitybio Inc. possesses several strengths that contribute to its competitive advantage:
- Strong research and development capabilities enable the company to innovate and develop cutting-edge therapies.
- Extensive intellectual property portfolio provides protection and potential revenue streams.
- Well-established partnerships with leading academic institutions enhance knowledge sharing and collaboration.
- Diverse product pipeline with potential for addressing a wide range of diseases and medical conditions.
- Strong financial position enables investment in research, development, and commercialization activities.
Weaknesses
Despite its strengths, Immunitybio Inc. faces certain weaknesses:
- Relatively small size and limited resources compared to larger pharmaceutical companies.
- Dependence on a few key individuals for the success of its research and product development efforts.
- Potential risks associated with clinical trial failures and regulatory approval challenges.
- Highly competitive industry with the presence of established players.
- Limited market access and distribution capabilities in certain regions.
Opportunities
Immunitybio Inc. can leverage the following opportunities to further its growth:
- Increasing demand for innovative and personalized therapies in the healthcare sector.
- Rapid advancements in biotechnology, genomics, and immunotherapy present potential breakthrough opportunities.
- Emerging markets offer untapped opportunities for expansion and market penetration.
- Potential collaborations and partnerships with pharmaceutical companies to enhance product development and commercialization.
- Growing focus on preventive healthcare and personalized medicine creates a favorable market environment.
Threats
Immunitybio Inc. faces various threats that could negatively impact its performance:
- Intense competition from well-established pharmaceutical companies with significant resources and market presence.
- Uncertainties related to changes in regulations and healthcare policies.
- Potential delays in clinical trials and regulatory approvals may impede product commercialization.
- Rapidly evolving technology landscape introduces the risk of obsolescence.
- Economic downturns and market fluctuations can impact funding and investment opportunities.
Immunitybio Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Immunitybio Segments
Immunitybio Revenue by Segment (1/2)
Max
Details
Immunitybio Revenue by Segment (2/2)
Max
Details
Immunitybio Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Immunitybio Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Immunitybio historical P/E ratio, EBIT multiple, and P/S ratio
Immunitybio annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Immunitybio shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Immunitybio forecasts and price targets in September 2026
Analyst Price Targets 2026Immunitybio Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 6/2/2026 | Maintained | Buy | – | |
| 5/21/2026 | Maintained | Buy | 52 | |
| 5/20/2026 | Maintained | Buy | – | |
| 5/5/2026 | Maintained | Buy | – | |
| 4/21/2026 | Maintained | Buy | – | |
| 4/8/2026 | Maintained | Buy | – | |
| 3/26/2026 | Maintained | Buy | – | |
| 3/23/2026 | Maintained | Buy | – | |
| 3/17/2026 | Maintained | Buy | – | |
| 3/9/2026 | Maintained | Buy | – |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Immunitybio Earnings Calls
Immunitybio Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 8/12/2026 | -0.09USD | - | 50.69 MUSD | - | 2026 Q2 |
| 5/11/2026 | -0.07USD | - | 43.93 MUSD | - | 2026 Q1 |
| 3/3/2026 | -0.10USD | - | 37.76 MUSD | - | 2025 Q4 |
| 11/6/2024 | -0.18USD | - | 4.45 MUSD | - | 2024 Q3 |
| 11/9/2022 | -0.23USD | - | 25,374.00USD | - | 2022 Q3 |
| 8/8/2022 | -0.24USD | - | 25,374.00USD | - | 2022 Q2 |
| 5/10/2022 | -0.22USD | - | 25,374.00USD | - | 2022 Q1 |
| 3/1/2022 | -0.21USD | - | 25,374.00USD | - | 2021 Q4 |
| 11/12/2021 | -0.20USD | - | 25,374.00USD | - | 2021 Q3 |
| 8/12/2021 | -0.12USD | - | 25,374.00USD | - | 2021 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Immunitybio stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Immunitybio shareholder structure
| % | Name |
|---|---|
3.77829% | |
2.53948% | |
2.34082% | |
2.16943% | |
1.80287% | |
1.15184% |
Immunitybio Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
64.80% | SEC ↗ | |
29.60% | SEC ↗ | |
24.70% | SEC ↗ | |
24.70% | SEC ↗ | |
12.00% | SEC ↗ | |
10.00% | SEC ↗ | |
9.30% | SEC ↗ | |
6.92% | SEC ↗ | |
4.80% | SEC ↗ |
Immunitybio Executives and Management Board
9 members · avg. age 63 · 33 % women
Mr. Richard Adcock (56)
President, Chief Executive Officer, Director · since 2020
10.95 M USD
Management
Dr. Patrick Soon-Shiong (71)
Executive Chairman of the Board, Global Chief Scientific and Medical Officer · since 2015
Mr. David Sachs (47)
Chief Financial Officer
Dr. Barry Simon (60)
Chief Corporate Affairs, Director · since 2007
Board of Directors
Ms. Cheryl Cohen (59)
Lead Independent Director
Mr. Michael Blaszyk (71)
Independent Director
Dr. Linda Maxwell (51)
Independent Director
Ms. Christobel Selecky (70)
Independent Director
Gen. (Retd.) Wesley Clark (80)
Independent Director
Frequently asked questions about Immunitybio
Immunitybio Inc. operates under a comprehensive business model focused on bringing innovative immunotherapies to patients. By leveraging its expertise in immunology, the company develops targeted treatments that harness the power of the immune system to combat various diseases, including cancer and infectious diseases. Immunitybio Inc. strives to address unmet medical needs by integrating cutting-edge technologies and advancing clinical research, with the ultimate goal of improving patient outcomes. With a robust pipeline and commitment to scientific excellence, Immunitybio Inc. seeks to revolutionize the way diseases are treated and provide hope for patients worldwide.
Immunitybio Inc is primarily active in the fields of biotechnology and immunotherapy. As a leading biotech company, Immunitybio Inc focuses on developing breakthrough treatments and therapies that harness the power of the immune system to combat diseases. With a strong emphasis on research and innovation, Immunitybio Inc aims to revolutionize healthcare by providing effective solutions for various medical conditions. Through its cutting-edge advancements in biotechnology and immunotherapy, Immunitybio Inc is dedicated to improving patient outcomes and making a significant impact in the industry.
The main competitors of Immunitybio Inc in the market are companies like Moderna Inc, BioNTech SE, Novavax Inc, and AstraZeneca PLC.
Immunitybio Inc is a leading biotechnology company known for its innovative immunotherapy treatments. Established in [year], Immunitybio has a rich history of developing groundbreaking therapies to combat various diseases. With a strong focus on cancer research, the company has made significant strides in revolutionizing the field of oncology. Immunitybio's cutting-edge technologies and advanced scientific approaches have positioned it as a key player in the biotech industry. Its dedication to improving patient outcomes and advancing medical knowledge has garnered widespread recognition and put Immunitybio at the forefront of the fight against cancer and other illnesses.
Immunitybio Inc has achieved several significant milestones. The company has made breakthrough advancements in the field of immunotherapy, with a focus on developing innovative treatments for cancer and infectious diseases. Immunitybio Inc has successfully conducted clinical trials to demonstrate the efficacy and safety of its novel therapies. Additionally, the company has secured strategic partnerships with leading institutions and organizations, further validating its scientific expertise. With its strong commitment to research and development, Immunitybio Inc continues to make remarkable progress in improving patient outcomes and revolutionizing the field of immunotherapy.
Immunitybio Inc is primarily present in the United States.
Immunitybio Inc represents values of innovation, resilience, and commitment to advancing healthcare. Committed to developing and delivering cutting-edge immunotherapies and vaccines, Immunitybio Inc aims to revolutionize the treatment of various diseases. With a strong corporate philosophy centered around patient-centricity and scientific excellence, the company strives to bring about positive changes in global healthcare. Immunitybio Inc seeks to harness the power of the immune system to combat diseases and improve patient outcomes. By combining expertise, technology, and a passion for improving lives, Immunitybio Inc is dedicated to making a significant impact in the field of immunotherapy and beyond.
Analysts currently set an average price target of 12.04 USD for the Immunitybio stock (median: 9.18 USD), implying +51.4 % versus the latest price. The consensus is based on 11 analyst ratings.
11 analysts currently rate the Immunitybio stock: 10 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Immunitybio to generate revenue of 225.58 M USD and earnings per share of -0.68 USD.
Converted at the current exchange rate, the Immunitybio share trades at 6.86 EUR (7.95 USD).
The Immunitybio share (IBRX) is listed on 4 stock exchanges, including: NASDAQ (IBRX), Frankfurt (26CA.F), München (26CA.MU), Düsseldorf (26CA.DU).
Immunitybio Inc is a US biotechnology company focused on developing immunotherapies. The company operates in three main areas: oncology, infectious diseases, and autoimmune diseases. Its goal is to produce innovative drugs that strengthen the immune system and fight diseases. Immunitybio focuses on developing cancer drugs that activate the immune system and target cancer cells. The company offers a range of immunotherapies based on different compounds and technologies. Its flagship product in oncology is the drug N-803, which aims to activate T-cells in the body and fight cancer. Immunitybio is currently conducting clinical trials with N-803 to evaluate its efficacy. In the field of infectious diseases, Immunitybio is developing vaccines and immunotherapies against various diseases such as influenza, HIV, and COVID-19. The company recently initiated a COVID-19 vaccine study testing a vaccine based on an adenoviral vector containing the spike protein of the virus. It is also working on developing vaccines against other infectious diseases such as dengue fever and malaria. In the field of autoimmune diseases, Immunitybio focuses on developing immunotherapies that can better regulate autoimmunity. The company is developing drugs based on various compounds, including T-cell receptor mimetics and antibodies against specific immune cells. Immunitybio has also developed a T-cell therapy that can be used for multiple sclerosis. In addition, Immunitybio offers services in genetic engineering and protein production. The company has an extensive platform technology used for the production of proteins, antibodies, and vaccines. It also offers customized proteins and antibodies for various applications. Immunitybio has established a strong partnership with the University of California, Los Angeles (UCLA) to support its research and development activities. The company has also formed partnerships with other companies and organizations in the healthcare sector to further enhance its products and services. Immunitybio's business model is based on the development and commercialization of immunotherapies and vaccines for different diseases. The company has a strong research and development pipeline and collaborates closely with other companies and organizations to expand its product and service offerings. With a robust platform technology and dedicated leadership, Immunitybio has the potential to revolutionize the healthcare industry and improve disease treatments.
The expected revenue of Immunitybio is 225.58 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Immunitybio is -669.42 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Immunitybio is currently -11.75. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Immunitybio stock.
The price-to-sales ratio (P/S) of Immunitybio is currently 34.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Immunitybio stock.
The Eulerpool Quality Score for Immunitybio is 4/10.
The ISIN of Immunitybio is US45256X1037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Immunitybio is A2QQ2E. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Immunitybio is IBRX. The ticker symbol is used to trade Immunitybio shares on the stock exchange.
Immunitybio paid dividends every year for the past 0 years.
Immunitybio is assigned to the 'Health' sector.
The dividends of Immunitybio are distributed in USD.
Immunitybio stock
Immunitybio Peer Group
Immunitybio Ticker
Immunitybio FIGI
All fundamentals and in-depth analysis of Immunitybio
Our stock analysis for Immunitybio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunitybio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.